Leiden, October 2026 — Initial laboratory results open a potential development route for targeted cancer therapies without requiring light activation.
GenLumina is developing a family of silver-based oncology payloads: SnB (SilvernanoBullet) and SnB* (SilvernanoBullet-star).
SnB: cytotoxic activity without light activation
Initial in vitro studies show dose-dependent cytotoxic activity of free SnB without illumination. These findings support further evaluation of SnB as a potential payload for antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs).
SnB: light activation to enhance activity*
SnB* is designed to enhance intracellular cytotoxic activity through light activation. It offers an additional development option where light delivery is feasible and provides a meaningful benefit.
Together, SnB and SnB* offer potential opportunities for ADC and PDC developers seeking new payloads.
The next step: targeted conjugates
GenLumina is evaluating whether antibody- and peptide-based delivery can bring SnB into target cells while retaining sufficient cytotoxic activity without light. Establishing target-dependent cell killing is a key next validation milestone.
“These findings are an exciting step for GenLumina. They suggest a potential development route without requiring light activation, which could simplify clinical development while preserving light activation as an additional option,” said CEO Gerco Kanbier
For more information or collaboration opportunities, please contact us